MultiplexDX Achieves ISO 9001:2015 Certification
We are proud to announce that MultiplexDX has successfully obtained the ISO 9001:2015 certification, reflecting our commitment to quality management and continuous improvement. This achievement underscores our dedication to delivering top-tier diagnostic solutions and maintaining the highest standards in all aspects of our operations.
This certification is a testament to the hard work and expertise of our entire team. We remain focused on driving innovation and excellence in personalized breast cancer diagnostics.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
